According to the results of a new study, combining cannabidiol (CBD) with the terpene beta-caryophyllene (BCP) may be an effective treatment option for chronic pain and depression, two conditions researchers say frequently overlap but are often managed separately.

The study, published in Pharmacological Research, used a chronic inflammatory pain model in mice, induced with Complete Freund’s Adjuvant (CFA). Mice were then evaluated with a range of pain and depression-related behavior tests. According to the researchers, those given the CBD–BCP combination displayed stronger pain relief than either compound on its own. They also showed measurable antidepressant-like effects.

On a biological level, the findings suggest that the benefits extend beyond symptom management. Immunohistochemistry revealed that the combined treatment reduced CFA-induced neuroinflammation, while proteomic analysis showed a downregulation of specific proteins linked to inflammation. This dual action, the authors note, may explain the observed improvements in both pain and mood symptoms.

“We found that mice treated with the CBD and BPC combination produced a synergistic pain-relieving effect in the chronic inflammatory pain model and exhibited antidepressant properties”, states the study. “Our IHC data also show that the CBD and BCP combination significantly reduced the neuroinflammation produced by CFA, and the proteomics showed downregulation of selected proteins involved in inflammation by the combination, compared to the individual effects of CBD and BCP.”

Researchers conclude by stating:

In conclusion, our current findings show that, in the CFA pain model, the combination of CBD and BCP produces a synergistic pain-relief effect while also having antidepressant properties. Additionally, our data show that the anti-inflammatory action of this combination may explain its beneficial effects on pain and depression. Therefore, our data suggest this combination as a potentially effective treatment for chronic pain and related depression.